Overview Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors Status: Unknown status Trial end date: 2019-10-01 Target enrollment: Participant gender: Summary Phase Ib/II study to evaluate the efficacy and tolerability of PM01183 in combination with olaparib in patients with advanced solid tumors. Phase: Phase 1/Phase 2 Details Lead Sponsor: Poveda, Andrés, M.D.Collaborators: AstraZenecaPharmaMarTreatments: Olaparib